Adult Depression Study - Protocol 3111-301-001
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients with Major Depressive Disorder (MDD) who have had an Inadequate Response to Antidepressants Alone
Description of Study: This is an approximately eight-week study to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy in patients with MDD who have had an inadequate response to antidepressants alone.
- Adults 18–65 diagnosed with MDD (otherwise medically stable)
- Inadequate response to current antidepressant therapy
Principal Investigator: Subhdeep Virk, MD
Funding/Study Sponsor: Allergan